At the end of the week, we should take a look back and notice the performance of several stocks. They include: Rite Aid Corporation (NYSE:RAD), Sprint Nextel Corporation (NYSE:S), Pfizer Inc. (NYSE:PFE), and Sirius XM Radio Inc (NASDAQ:SIRI).
Rite Aid Corporation (NYSE:RAD) was one of the big movers on the market during the week. The stock gained 29.78% over the past five days and closed on Friday 8.96% higher at $2.31 in turnover worth about $59 million, the second largest on NYSE. Rite Aid Corporation (NYSE:RAD) advanced mainly on Thursday, when the company published its results for the fourth quarter of 2012 as well as for the full year of 2012. In this way, Rite Aid Corporation (NYSE:RAD)’s net income for 2012 totaled $118.1 million or $0.12 per diluted share. “In addition to setting a new company record for full-year Adjusted EBITDA [$1,128.4 million], we generated full-year net income for the first time since fiscal 2007,” Rite Aid Corporation (NYSE:RAD) quoted its Chairman, President and CEO, John Standley in a statement.
Sprint Nextel Corporation (NYSE:S) edged down by 0.16% over the week and ended 0.64% lower at $6.22 on Friday, with turnover worth almost $46 million, the third largest on NYSE. Zolmax News quoted Stock Rating Network.com that JP Morgan Chase analysts have reaffirmed the “neutral” rating for Sprint Nextel Corporation (NYSE:S), having the target price set at $6.00. Also, CrazyJoys.com reported that Sprint Nextel Corporation (NYSE:S) is thinking about extending the customer base in Indiana and California by launching LTE network in these states.
A growth was also experienced by Pfizer Inc. (NYSE:PFE), which advanced by 5.4% over the week and inched up by 0.1% to $30.67 in deals worth $39.1 million on Friday. In a press release issued on Wednesday, Pfizer Inc. (NYSE:PFE) announced about its investigational compound palbociclib, which has got Breakthrough Therapy designation by the FDA for the potential treatment of patients with breast cancer. “We appreciate the opportunity that Breakthrough Therapy designation provides to work closely with the FDA on the development of palbociclib, […] Palbociclib is one example of Pfizer Inc. (NYSE:PFE)’s commitment to identifying and translating innovative science into meaningful new treatment options for cancer patients,” the statement quoted Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer Inc. (NYSE:PFE)’s Oncology business unit.
Sirius XM Radio Inc (NASDAQ:SIRI) increased by 2.33% during the past five days and lost 2.38% to $3.08 in turnover worth about $37.8 million on Friday. Sirius XM Radio Inc (NASDAQ:SIRI) is planning to release its first quarter results on April 30. Analyst Jason Basinet from Citi Research Equities said that Sirius XM Radio Inc (NASDAQ:SIRI) will not initiate a transformative acquisition to expand its telematic service offerings due to the large costs of acquisition, but will rather “invest in the telematic segment to fill in missing capabilities through organic investments augmented by targeted, low-cost acquisitions instead of a transformative acquisition,” according to ValueWalk.